Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 12/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | CLK3 | P49761 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL643176 | 0.85 | GCK (0.62) | GCKNPC1RAB9A | |
| SCHEMBL15780522 | 0.84 | GCK (0.54) | GCKNPC1RAB9AIRAK4 | |
| SCHEMBL12101372 | 0.77 | GCK (0.48) | GCKNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL644304 | 0.76 | GCK (0.64) | GCKNPC1RAB9A | |
| SCHEMBL643753 | 0.76 | GCK (0.58) | GCKNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL12101384 | 0.76 | GCK (0.58) | GCKNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL644899 | 0.73 | GCK (0.62) | GCKNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL642856 | 0.73 | GCK (0.58) | GCKNPC1RAB9AALDH1A1IRAK4 | |
| SCHEMBL644978 | 0.73 | GCK (0.68) | GCK | |
| SCHEMBL644554 | 0.73 | GCK (0.70) | GCKNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463283-A1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | Pfizer Products Inc. (US) | 2012-06-13 | — | — | EP | disclosed |